Human interleukin-2

Generic Name: Human interleukin-2

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: FNO32LO217

Background: Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor, Adult

Interventions: Drug: FT516
Drug: Avelumab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: IL-2

First Posted Date: 2020-09-16

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 12

Registration Number: NCT04551885

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases

Not Applicable

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: IL-2

First Posted Date: 2020-05-21

Last Posted Date: 2022-08-18

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 46

Registration Number: NCT04397107

Locations: 🇨🇳
Sirui Yang, Changchun, Changchun/Jilin, China

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura

Not Applicable

Completed

Conditions: Purpura, Schoenlein-Henoch

Interventions: Drug: IL-2

First Posted Date: 2020-05-14

Last Posted Date: 2022-08-18

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 59

Registration Number: NCT04387942

Locations: 🇨🇳
Sirui Yang, Changchun, Changchun/JiLin, China

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Phase 2

Withdrawn

Conditions: Refractory Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia

Interventions: Biological: Cytokine induced memory-like NK cells
Procedure: Leukapheresis
Drug: Fludarabine
Drug: Ara-C
Drug: G-CSF
Drug: Interleukin-2

First Posted Date: 2020-04-21

Last Posted Date: 2023-04-04

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT04354025

Natural Killer-cell Therapy for Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia, Relapsed, Adult
Acute Myeloid Leukemia Refractory

Interventions: Biological: UCB-NK cells
Drug: IL-2

First Posted Date: 2020-04-15

Last Posted Date: 2024-04-23

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 23

Registration Number: NCT04347616

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Phase 1

Completed

Conditions: Leukemia, Acute Myeloid
Leukemia, Acute Lymphoblastic

Interventions: Biological: Expanded Haploidentical Natural Killer cells
Drug: IL-2

First Posted Date: 2020-03-30

Last Posted Date: 2022-03-02

Lead Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

Target Recruit Count: 10

Registration Number: NCT04327037

Locations: 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus

Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy

Phase 2

Conditions: Inflammatory Myopathy

Interventions: Drug: Interleukin-2
Drug: ciclosporin and corticosteroid

First Posted Date: 2020-01-23

Last Posted Date: 2020-01-23

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 20

Registration Number: NCT04237987

A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Phase 2

Recruiting

Conditions: Neuroendocrine Tumors
Vaccination
Head Neck Tumors
Soft Tissue Sarcoma
Rare Cancer

Interventions: Biological: Autologous DC vaccine
Drug: Interleukin-2

First Posted Date: 2019-11-18

Last Posted Date: 2020-04-22

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 51

Registration Number: NCT04166006

Locations: 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Biological: IOV-2001
Drug: Low dose IL-2
Drug: High dose IL-2
Drug: IL-2

First Posted Date: 2019-11-07

Last Posted Date: 2024-06-18

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 70

Registration Number: NCT04155710

Locations: 🇺🇸
Allegheny Health, Pittsburgh, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients

Conditions: Infection

Interventions: Drug: IL-2

First Posted Date: 2019-10-23

Last Posted Date: 2019-10-23

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 500

Registration Number: NCT04136106

Locations: 🇨🇳
Peking Universtiy People's Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy